About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 73211 record(s)
Req # A-2020-001088
The emails, briefing notes, recordings, text messages, and correspondence pertaining to the consultations undertaken by the Advisory Council on the Implementation of National Pharmacare. Timeframe: January 1,2018 to September 24, 2020.Organization: Health Canada
September 2024
Req # A-2023-000153
Records that include information on the following topics. Date range January 1, 2020 to May 1, 2023. What Health Canada knew about the World Health Organization's (WHO) position on Philip Morris‘ minority ownership stake in Medicago. When…Organization: Health Canada
September 2024
Req # A-2023-000618
The disclosable inspection document(s) listing the Inspector’s detailed observations, conditions found, and any follow-up expected by Health Canada for the human drugs drug establishment licence Good Manufacturing Practices (GMP) inspection of the…Organization: Health Canada
September 2024
Req # A-2023-001136
With respect SUMMARY MONTHLY SAFETY REPORT #5, the date when this report was received; the date when the review was completed and by whom including expertise/specialty; findings including: newly identified signals, both validated and invalidated, as…Organization: Health Canada
September 2024
Req # A-2023-001241
All documents and correspondence which the rapid test supplier BTNX, Inc., submitted to Health Canada as it applied for approval to sell the COVID-19 antigen test with the device identifiers COV-19CSHC, COV-19CSHC1, COV-19CSHC2, COV-19CSHC5, COV-…Organization: Health Canada
September 2024
Req # A-2023-001361
With respect to drug submission for aripiprazole which appears in the list of “Generic Drug Submissions Under Review” dated 2024-01-19, the initial cover letter(s) indicating the brand name of the reference drug product and the dosage form of the…Organization: Health Canada
September 2024
Req # A-2023-001420
All documents relating to the following medical devices: Company Identification (ID): 122369, Device name: 68882, DAP DIPHOTERINE and 68883, DAP HEXAFLUORINE, Company name: Prevor, Date range: 01 January 2003 to 01 Jan 2022.Organization: Health Canada
September 2024
Req # A-2023-001442
A list of external individuals/groups who provided responses to BOTH these external stakeholder consultations (Advanced Therapeutic Products (ATP) and Point of Care Chimeric Antigen Receptor T-cell (CAR T)), a list of the external representatives…Organization: Health Canada
September 2024
Req # A-2023-001451
The Abbreviated New Drug Submission (ANDS) seeking approval of a product containing the medicinal ingredient desmopressin acetate, which was accepted into review on or after March 1, 2022 but before December 1, 2022, received a notice/letter from…Organization: Health Canada
September 2024
Req # A-2023-001606
The most recent Module 2.3: Quality Overall Summary (QOS) submitted the sponsor for the Semaglutide Abbreviated New Drug Submission (ANDS).Organization: Health Canada
September 2024